ArticleDocumenta ophthalmologica. Advances in ophthalmology2026
Electronegative ERG revealing melanoma-associated retinopathy in a patient with trametinib-associated retinopathy.
Article in Documenta ophthalmologica. Advances in ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo describe electrophysiologic detection of melanoma-associated retinopathy (MAR) in a patient initially presumed to have isolated trametinib-associated retinopathy.
methodsCase report incorporating spectral-domain optical coherence tomography (OCT), fundus photography and fundus autofluorescence, serial full-field electroretinography (ffERG), and serum anti-transient receptor potential melastatin 1 (TRPM1) autoantibody testing by Western blot analysis.
resultsA 68-year-old woman receiving trametinib for metastatic vulvar melanoma developed bilateral multifocal serous retinal detachments consistent with MEK inhibitor-associated retinopathy (MEKAR). The subretinal fluid resolved after discontinuation of trametinib, but nyctalopia persisted. ffERG performed according to the International Society for Clinical Electrophysiology of Vision (ISCEV) Standard demonstrated bilateral electronegative dark-adapted (DA) 3.0 responses with relatively preserved a-waves and markedly reduced b-waves, consistent with predominant post-photoreceptoral dysfunction. Serum testing demonstrated anti-TRPM1 autoantibody positivity. At approximately 6 months after the initial ffERG, visual acuity had improved, whereas nyctalopia persisted and ffERG findings remained essentially unchanged, with persistent bilateral electronegative DA 3.0 responses. These findings supported concomitant MAR in addition to MEKAR.
conclusionsIn patients with melanoma who develop MEKAR during trametinib therapy, persistent nyctalopia or other visual symptoms despite anatomical resolution should prompt evaluation for concomitant paraneoplastic retinopathy. An electronegative ffERG together with anti-TRPM1 autoantibody positivity can provide important supportive evidence for MAR.
Indexed as
Identifiers
42684571What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.